CHICAGO — Amgen’s month-to-month weight problems candidate led to substantial weight reduction however a excessive charge of unintended effects and discontinuations in a mid-stage trial, outcomes that assist the corporate’s resolution to make use of a slower dosing schedule to make the drug extra tolerable in additional testing.
Within the Part 2 research, sufferers with weight problems taking the injectable drug, known as MariTide, misplaced as much as 16.2% of their weight in a single 12 months when considering all contributors no matter discontinuations. Sufferers misplaced as much as 19.9% when analyzing solely those that stayed on therapy.
Sufferers with weight problems and sort 2 diabetes misplaced as much as 12.3% of their weight when analyzing all contributors and as much as 17% when analyzing those that didn’t discontinue, based on outcomes that have been revealed Monday within the New England Journal of Medication and might be offered right here on the American Diabetes Affiliation assembly.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
